Kristof Roox
Overview
Pharmaceutical and life sciences companies often have to deal with complex patent litigation. They require help from someone with a pragmatic, creative approach, and this is Kristof Roox’s particular strength. Clients reach out to Kristof for his tenacity in the courtroom as well as his to-the-point counseling on every aspect of intellectual property law.
Career & Education
- University of London (Queen Mary and Westfield College), LL.M., intellectual property law, 1996
- Free University of Brussels (Vrije Universiteit Brussel), J.D., cum laude, licentiate degree law, 1994
- Heilig-Hartcollege, Maasmechelen, 1989
- Belgium
- Intellectual Property Council, section Industrial Property, Belgian Government, FPS Economy
- Editorial Board, IRDI
- Board of Governors, University of Brussels Law Alumni
- Visiting Professor Patent Law, Maître des Conférences, University of Liège (2010-2012)
- Assistant Professor Private International Law, University of Gent (1998-2004)
- Dutch
- English
- French
- German
Kristof Roox, with his impactful commercial insight, is a wellspring of creativity, dynamism and incisive litigatory prowess, adeptly navigating high-stakes matters.
— IAM Patent, 2025
Kristof's Insights
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
On November 13, 2025, the president of the French-speaking Brussels Enterprise Court ruled in the long-running battle between Sandoz and Regeneron about the correct interpretation of the EU’s Supplementary Protection Certificate (SPC) Manufacturing Waiver Regulation regarding exports to a non-EU market. The Brussels Court dismissed Regeneron’s claim that Sandoz had provided a defective notification and agreed with Sandoz’s interpretation of the Regulation.
Speaking Engagement | 09.25.25
"Global Sustainability and Competitiveness Summit," Crowell & Moring Seminar, Brussels, BE.
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions
Representative Matters
- Regularly represents several major international pharmaceutical companies in patent infringement and invalidity litigation.
- Represents several clients in parallel import cases.
- Represented a client in a dispute regarding a new type of shock absorber for cars.
- Represents a major Belgian cable network provider in one of the most important copyright cases in Belgium regarding “direct injection,” “simulcasting” and “all rights included” contracts.
- Represents an association of music festivals in a major dispute concerning copyright royalties and abuse of dominance.
- Represented the Belgian government in high-profile litigation concerning the alleged non-respect of several court orders.
- Represents software manufacturers in licensing disputes.
- Represents a client in a white collar crime / public procurement matter.
Kristof's Insights
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
On November 13, 2025, the president of the French-speaking Brussels Enterprise Court ruled in the long-running battle between Sandoz and Regeneron about the correct interpretation of the EU’s Supplementary Protection Certificate (SPC) Manufacturing Waiver Regulation regarding exports to a non-EU market. The Brussels Court dismissed Regeneron’s claim that Sandoz had provided a defective notification and agreed with Sandoz’s interpretation of the Regulation.
Speaking Engagement | 09.25.25
"Global Sustainability and Competitiveness Summit," Crowell & Moring Seminar, Brussels, BE.
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions
Recognition
- Legal 500 EMEA: Belgium, Intellectual Property: Hall of Fame, 2020–present
- Legal 500 EMEA: Belgium, Industry Focus: Healthcare & Life Sciences, Hall of Fame, 2025
- Legal 500 EMEA: Belgium, EU Regulatory: Pharma, Medical Devices & Biotech, Leading Partner, 2018–present
- Chambers Europe: Belgium, Intellectual Property, Band 1, 2006–present
- Chambers Europe: Belgium, Life Sciences: Domestic, Band 3, 2006–present
- IAM Patent 1000: Litigation and Transactions, Gold, 2014–present
- IAM Strategy 300: World leading IP Strategist for Legal, Medical Devices and Pharmaceuticals/Life Sciences, 2024–present
- IAM Global Leaders: Global Leader, 2022–present
- Managing Intellectual Property IP Stars: Patent Star, 2014–present
- World Trademark Review: Benelux: Belgium, Silver, 2025
Kristof's Insights
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
On November 13, 2025, the president of the French-speaking Brussels Enterprise Court ruled in the long-running battle between Sandoz and Regeneron about the correct interpretation of the EU’s Supplementary Protection Certificate (SPC) Manufacturing Waiver Regulation regarding exports to a non-EU market. The Brussels Court dismissed Regeneron’s claim that Sandoz had provided a defective notification and agreed with Sandoz’s interpretation of the Regulation.
Speaking Engagement | 09.25.25
"Global Sustainability and Competitiveness Summit," Crowell & Moring Seminar, Brussels, BE.
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions
Insights
A Christmas gift for the biosimilar industry: Landmark judgment in SPC Manufacturing Waiver case
|12.31.24
Kluwer Patent Blog
International Litigation: Litigating Patents in Europe: A Whole New Ball Game
|01.10.24
Litigation Forecast 2024
- |
08.15.20
Crowell & Moring
Safe Harbors in Europe: An Update on the Research and Bolar Exemptions to Patent Infringement
|07.30.15
Nature Biotechnology, Vol. 33, No. 7
Counterfeit remains seized despite expiration of patent, decides Antwerp Judge
|02.19.15
Kluwer Patent Blog
Regulatory Forecast 2015: What Corporate Counsel Need to Know for the Coming Year
|01.31.15
a Crowell & Moring LLP publication
De Minimis in Belgian Patent Law
|01.01.15
I.R.D.I.
U.S. Law Firm Crowell & Moring Confirms Its Europe Expansion Through Its Brussel Office
|06.23.22
Leaders League
Crowell & Moring Adds Veteran Disputes Partner In Brussels From Allen & Overy
|06.22.22
The Global Legal Post
Practices
- Intellectual Property — Brussels Practice
- Dispute Resolution — Brussels Practice/IP
- Life Sciences — Brussels Practice
- Trademarks and Designs — Brussels Practice
- Copyright — Brussels Practice
- Copyright Counseling and Litigation
- Patents — Brussels Practice
- European Patents and Unified Patent Court — Brussels Practice
- Brussels Practice
- Technology, Media, and Telecommunications — Brussels Practice
- Health Care
- Financial Services
- Life Sciences
- Life Sciences — Intellectual Property
Industries
Kristof's Insights
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
On November 13, 2025, the president of the French-speaking Brussels Enterprise Court ruled in the long-running battle between Sandoz and Regeneron about the correct interpretation of the EU’s Supplementary Protection Certificate (SPC) Manufacturing Waiver Regulation regarding exports to a non-EU market. The Brussels Court dismissed Regeneron’s claim that Sandoz had provided a defective notification and agreed with Sandoz’s interpretation of the Regulation.
Speaking Engagement | 09.25.25
"Global Sustainability and Competitiveness Summit," Crowell & Moring Seminar, Brussels, BE.
Client Alert | 10 min read | 08.27.25
The New EU “Pharma Package”: Advertising – A Comparison of Commission/Parliament/Council Positions




